Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsPlasma membrane transporters in modern liver pharmacologyIntestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Clinically significant psychotropic drug-drug interactions in the primary care setting.Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functionsInteraction of innovative small molecule drugs used for cancer therapy with drug transporters.Contribution of tumoral and host solute carriers to clinical drug response.Transporter-mediated drug-drug interactions.Novel models for assessing blood-brain barrier drug permeation.Bioavailability of phytochemicals and its enhancement by drug delivery systems.Experimental models for predicting drug absorption and metabolism.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.Loperamide-Related Deaths in North Carolina.Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs.Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and RosuvastatinDrug transporter regulation in tumors by DNA methylation.Detection of statin cytotoxicity is increased in cells expressing the OATP1B1 transporter.Tissue distribution and phenobarbital induction of target SLC- and ABC- transporters in cattle.Tumor suppressor gene OSCP1/NOR1 regulates apoptosis, proliferation, differentiation, and ROS generation during eye development of Drosophila melanogaster.Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs.Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.Organic anion transporting polypeptide 2 transports valproic acid in rat brain microvascular endothelial cells.Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types.Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.Role of Hepatic Drug Transporters in Drug Development.Development of a high-throughput mass spectrometry based analytical method to support an in vitro OATP1B1 inhibition screening assay.Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2.Nanoparticles and Controlled Delivery for Bioactive Compounds: Outlining Challenges for New "Smart-Foods" for Health.Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
P2860
Q24273350-05EE3A01-EE23-455D-A871-EBF413B06A90Q26787099-CBAA24F6-36CB-4A57-A5BF-CAA748C5CFCCQ26829263-880C5D25-9036-4D95-8252-BA897DCA6995Q33630549-8819F800-0686-4E8C-A3F3-F71D60825BD7Q34646772-C30B50A2-07AB-4CA5-9D00-BC14B4BC04C1Q35104220-5D3A722D-2A4F-4431-B278-192D43ABB725Q35549264-B455BFA8-F606-47B9-9BDE-FEF2DBE2F830Q35708124-10EDF12F-3DC3-4AB3-A228-01A96F18A82CQ35946876-E6222F60-8B04-4DED-AB6C-45BAA18730B8Q37905033-05F1F57E-9129-4418-9626-9676689227EBQ37999058-3F801692-EFE4-4877-92CB-D4F09B2F503FQ38084084-1FC5AEAC-C647-467E-ABE5-37AEC2D60ABAQ38107970-8B955207-303C-4C2E-B160-02EC168F3FE8Q38183877-5608F2BC-BC36-47D3-AB98-91DC1275F8A0Q38374432-636143B1-86EC-4953-8E8C-514361585D1BQ38913158-5DCAA555-0221-48DA-85EA-37A9DCB39D0DQ39001980-FBA02079-22BA-4A36-83F5-6CEBF5494209Q39195090-7792CF80-FD69-4810-8493-B6A87BF4BD1AQ39198686-9FB5E616-3906-47C9-BFA6-1254B78D0DDCQ39472771-E090CBC7-F646-4506-888C-1481000B9CA6Q42025168-0FC92C2A-C2CF-4205-802B-29ACC8D5E00CQ42092470-5E034B29-2D15-429D-99E5-CB8B6E5A3261Q42132649-706B3FD0-99C9-4A7F-B851-DA351CA56A7FQ42712029-2E14A31B-88B0-48F9-A1CA-238978C66E69Q46033735-D428B2EF-9DF8-4C8A-96E0-9F67635EDA37Q46663272-1DAFC3F4-2B1F-47E6-A2CB-25D5907F7523Q47097992-F232C488-360F-4169-88AE-14F2D2F14054Q47808595-19A870DB-F482-490D-83F2-2F15ED7697D0Q48759126-651777E9-349F-4340-AC8E-6A46652051DEQ49472868-C60739B8-1656-4D5E-8F32-04F4341E9ACAQ51579192-D8592C6C-A71F-4738-B2DF-3B7F44163E0CQ51659233-CEBAC9B3-45E2-4E00-831B-E57300DDE044Q54267452-FC18C4B0-98B1-4395-A0D2-626181881A04Q55041942-61808A70-0013-4B06-BAA8-969A80AFE0E8Q55252923-49A92457-4453-4D41-8E69-73D191227190Q58774865-CE8109D5-FD49-4F11-B7E6-AF31F43D42C5
P2860
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@en
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@nl
type
label
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@en
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@nl
prefLabel
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@en
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@nl
P2860
P356
P1476
Transporter-mediated drug upta ...... nts of adverse drug reactions.
@en
P2093
P2860
P2888
P304
P356
10.1038/CLPT.2010.354
P407
P577
2011-04-06T00:00:00Z
P5875
P6179
1027785720